Trump's order to split the MMR vaccine into individual shots threatens to reverse decades of pediatric vaccine bundling, forcing manufacturers and distributors to source millions more syringes, vials, and cold-chain shipments. Procurement teams and clinics face uncertain demand forecasts and rising consumables costs.
Clinicians and public health officials warn the executive order to split the MMR vaccine and space out injections could reduce childhood immunization completion. Pediatric practices face more visits, more documentation, and higher costs with no clinical benefit identified.
Biopharma executives face a potential forced revival of discontinued single-antigen measles, mumps, and rubella vaccines, requiring new manufacturing lines and regulatory work. Analysts estimate tens of millions in upfront costs and years of development before any unbundled schedule could be supplied.
Source: troyrecord.com · greeleytribune.com